Roche gets FDA nod for Rozlytrek to treat ROS1-positive NSCLC

This article was originally published here

The company has also received accelerated approval for Rozlytrek to treat adult and paediatric patients 12 years of age and older with solid tumours, which have a neurotrophic

The post Roche gets FDA nod for Rozlytrek to treat ROS1-positive NSCLC appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply